Wegovy for Weight Loss: How Semaglutide Works and the Evidence

Wegovy sits near the center of nearly every weight-loss search this year, so it helps to separate what the molecule actually does from the marketing around it. Explore the full Peptides & GLP-1 library.

People typing "Wegovy for weight loss" usually want three things: a clear picture of the mechanism, an honest read of the trial data, and a sense of who the drug is not built for. This article walks through each, using only what the published record and FDA labeling establish as of April 2026, then turns to the genetic variables that sit beneath any GLP-1 decision.

What semaglutide does inside the body

Wegovy is a selective glucagon-like peptide-1 (GLP-1) receptor agonist. When it binds the GLP-1 receptor it slows how quickly the stomach empties, softens the glucose rise that follows a meal, and amplifies satiety signaling in the hypothalamus. For many people the practical result is a smaller appetite and steadier post-meal blood sugar — two levers that both feed into weight management rather than one standalone "fat-burning" effect.

It is worth naming what this is not. Semaglutide does not chemically dissolve fat or override metabolism by force. It changes the signals that govern hunger and fullness, which is why food environment, protein intake, and activity still matter alongside it.

Reading the STEP trial evidence

The weight-management data for Wegovy come from the STEP clinical trial program. Across those studies, average weight reduction reported in the published literature falls in roughly the 5–22% range relative to baseline body weight at study endpoints, varying by compound, dose, and the population studied. Those numbers describe trial cohorts, not promises; the manuscripts and FDA labeling remain the controlling sources, and an individual’s result can land anywhere along or outside that span.

Where the FDA label draws the lines

Wegovy earned FDA approval for chronic weight management in 2021, for adults with a BMI of 30 or higher, or 27 or higher alongside at least one weight-related condition. The label is the document that governs approved indications, dosing, contraindications, and warnings. Off-label use exists in practice and rests on prescriber judgment, but it is not a marketing category and not something a blog can advise.

Safety signals and who should steer clear

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. More serious events reported with Wegovy include pancreatitis, gallbladder disease, and acute kidney injury. The label also carries a boxed warning tied to thyroid C-cell tumor risk seen in rodent studies.

Absolute contraindications

Wegovy should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A full medical history — including pancreatitis, severe gastrointestinal disease, and kidney considerations — belongs in a conversation with a qualified provider before any GLP-1 pathway protocol begins.

Your metabolism has a genetic starting point

Two people can follow the same plan and respond differently, and part of that difference is written into their DNA. Common variants in FTO influence appetite and adiposity set-point, while GLP1R, MC4R, and TCF7L2 shape GLP-1 signaling, satiety, and glucose handling. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights to map that baseline biology. It never predicts how you will respond to Wegovy or set a dose — it simply gives you and your provider pathway-level context. PlexusDx offers semaglutide through its Weight Management Protocols, available as Semaglutide Injection and Semaglutide Oral, and the genetic read is the "test before you invest" step in front of it.

Setting realistic expectations

Because the trial figures describe averages across study groups, a single person’s experience can look different. Weight change tends to build gradually rather than all at once, and it depends on adherence, the dose reached under a provider’s supervision, and the everyday factors around eating and activity that semaglutide does not replace. The gastrointestinal side effects noted earlier are often most noticeable while the dose is being raised, which is one reason providers escalate slowly and follow up. Framing Wegovy as one input into a managed plan — rather than a standalone fix — keeps expectations honest and makes the follow-up conversations with your clinician more useful over time.

Frequently Asked Questions

How does Wegovy actually cause weight loss?

It engages the GLP-1 receptor, which slows gastric emptying, strengthens fullness signals in the brain, and steadies post-meal glucose. The net effect for many people is eating less without white-knuckling it. Individual results vary, and the STEP trial figures describe study groups rather than any single person’s outcome.

What weight change did the trials show?

Published STEP-program literature reports average reductions in roughly the 5–22% range of baseline body weight at study endpoints, differing by dose and population. These are cohort averages drawn from the manuscripts and FDA labeling, not personal guarantees, and your provider can frame what is realistic for your situation.

Who should not take Wegovy?

Anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 is contraindicated. Extra caution applies with prior pancreatitis, severe gastrointestinal disease, or certain kidney conditions. The complete list lives in the FDA label, so review your history with a provider first.

Does the genetic test tell me if Wegovy will work?

No. The Precision Peptide Genetic Test does not predict response to Wegovy or any medication. It reports pathway-level variants such as FTO, and MC4R that describe your baseline appetite and energy-balance biology, giving your provider added context rather than a forecast of drug outcomes.

Continue learning inside the PlexusDx Education Hub. Browse more Peptides & GLP-1 education.